Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAccepted Article

Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.

Giovanni Cagnotto, T.H. Lennart Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno and Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: https://doi.org/10.3899/jrheum.211199
Giovanni Cagnotto
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T.H. Lennart Jacobsson
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emil Rydell
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Eberhard
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Compagno
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl Turesson
This work was supported by The Swedish Research Council [grant number 2015-02228], The Swedish Rheumatism Association [grant number R-664091] and Lund University [grant number ALFSKANE-446501]. Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; Department of Rheumatology, Skane University Hospital, Malmö; Department of Rheumatology and Inflammation Research, Sahlgrenska Acadmy, Gothenburg University, Gothenburg, Sweden. Conflict of interest: G. Cagnotto: no financial disclosures. TH L. Jacobsson: lecture and consulting fees from Novartis, Eli-Lilly and Janssen. E. Rydell: no financial disclosures. A. Eberhard: no financial disclosures. M. Compagno: consulting fees from Abbvie and Sanofi Aventis. C. Turesson: consulting fees from Roche, speaking fees from Abbvie, Bristol Myers-Squibb, Nordic Drugs, Pfizer and Roche, and an unrestricted grant from Bristol Myers-Squibb. Corresponding author: Cagnotto Giovanni, Reumatologimottagning, Jan Waldenströms gata 1b, 20502 Malmö e-mail: Giovanni.cagnotto@med.lu.se
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective The aim of the present study was to investigate if the relation between sex and clinical outcomes in early rheumatoid arthritis varies by autoantibody status.

Methods Two inception cohorts of consecutive patients with early RA (symptom duration ≤12 months) in the Southern Region of Sweden were investigated. Patients were stratified by anti-citrullinated peptide antibody (ACPA) status. The primary outcome was remission (DAS28<2.6) at 12 months. Secondary outcomes were remission at 6 months and EULAR good response compared to baseline at 6 and 12 months. In logistic regression models, adjusted for age, DAS28 and HAQ at baseline, the relation between sex and clinical outcomes, stratified by ACPA status, was investigated.

Results In total 426 patients with early RA were included, 160 ACPA-negative and 266 ACPA-positive. At 12 months, 27% of females and 24% of males with ACPA-positive RA achieved DAS28 remission. In ACPA-negative RA, 16% of females and 49% of males achieved DAS28 remission at 12 months. Males had higher odds of reaching remission at 12 months in the ACPA-negative patient group (pooled adjusted OR 4.79, 95% CI 1.97-11.6), but not in the ACPA-positive group (pooled adjusted OR 1.06, 95 % CI 0.49-2.30).

Conclusion Male sex was associated with better clinical outcomes in ACPA-negative early RA, but not in ACPA-positive early RA. The poor outcomes in females with early seronegative RA suggest that this represents a difficult to treat patient group.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 49, Issue 6
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.
Giovanni Cagnotto, T.H. Lennart Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno, Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: 10.3899/jrheum.211199

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Male Sex Predicts a Favorable Outcome in Early ACPA-negative Rheumatoid Arthritis: Data From An Observational Study.
Giovanni Cagnotto, T.H. Lennart Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno, Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: 10.3899/jrheum.211199
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Evaluation of patients with rheumatoid arthritis in teleconsultation during the first wave of the COVID-19 pandemic
  • Anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease after vaccination with COVID-19 mRNA vaccines
  • Novel Biomarker of Collagen Degradation can Identify Patients Affected with both Axial Spondyloarthritis and Crohn's Disease
Show more Accepted Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire